AMP‐activated protein kinase as a mediator of mitochondrial dysfunction of multiple sclerosis in animal models: A systematic review
- 25 February 2024
- journal article
- review article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 239 (5)
Abstract
Multiple sclerosis (MS) is a chronic central nervous system (CNS) disorder characterized by demyelination, neuronal damage, and oligodendrocyte depletion. Reliable biomarkers are essential for early diagnosis and disease management. Emerging research highlights the role of mitochondrial dysfunction and oxidative stress in CNS disorders, including MS, in which mitochondria are central to the degenerative process. Adenosine monophosphate‐activated protein kinase (AMPK) regulates the mitochondrial energy balance and initiates responses in neurodegenerative conditions. This systematic review, following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, aimed to comprehensively assess the literature on AMPK pathways, mitochondrial dysfunction, and in vivo studies using MS animal models. The search strategy involved the use of AMPK syntaxes, MS syntaxes, and animal model syntaxes. The PubMed, Scopus, Web of Science, and Google Scholar databases were systematically searched on August 26, 2023 without publication year restrictions. The review identified and analyzed relevant papers to provide a comprehensive overview of the current state of related research. Eight studies utilizing various interventions and methodological approaches were included. Risk of bias assessment revealed some areas of low risk but lacked explicit reporting in others. These studies collectively revealed a complex relationship between AMPK, mitochondrial dysfunction, and MS pathogenesis, with both cuprizone and experimental autoimmune encephalomyelitis models demonstrating associations between AMPK and mitochondrial disorders, including oxidative stress and impaired expression of mitochondrial genes. These studies illuminate the multifaceted role of AMPK in MS animal models, involving energy metabolism, inflammatory processes, oxidative stress, and gene regulation leading to mitochondrial dysfunction. However, unanswered questions about its mechanisms and clinical applications underscore the need for further research to fully harness its potential in addressing MS‐related mitochondrial dysfunction.Keywords
This publication has 41 references indexed in Scilit:
- Experimental Autoimmune Encephalomyelitis in the MouseCurrent Protocols, 2021
- Metformin Therapy Attenuates Pro-inflammatory Microglia by Inhibiting NF-κB in Cuprizone Demyelinating Mouse Model of Multiple SclerosisNeurotoxicity Research, 2021
- Metformin accelerates myelin recovery and ameliorates behavioral deficits in the animal model of multiple sclerosis via adjustment of AMPK/Nrf2/mTOR signaling and maintenance of endogenous oligodendrogenesis during brain self-repairing periodPharmacological Reports, 2019
- RETRACTED ARTICLE: Oligoprotective effect of metformin through the AMPK-dependent on restoration of mitochondrial hemostasis in the cuprizone-induced multiple sclerosis modelJournal of Molecular Histology, 2019
- The mitochondrial transcription factor TFAM in neurodegeneration: emerging evidence and mechanismsFEBS Letters, 2018
- Modelling MS: Chronic-Relapsing EAE in the NOD/Lt Mouse Strain2015
- AMP-Activated Protein Kinase Signaling Protects Oligodendrocytes that Restore Central Nervous System Functions in an Experimental Autoimmune Encephalomyelitis ModelThe American Journal of Pathology, 2013
- Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesionsGlia, 2012
- Signaling and Regulatory Functions of Bioactive Sphingolipids as Therapeutic Targets in Multiple SclerosisNeurochemical Research, 2012
- Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patientsAnnals of Neurology, 2006